Pitch  & Partner

 

 

As funding remains a major hurdle for antibiotic and rapid diagnostics development, hear the perspective of current funding agencies and initiatives such as CARB-X, GARDP, and AMR Centre, as well as successful partnering and capital case studies that contributed to advancing the development of innovative antimicrobials and rapid tests. Over 20+ cutting edge biotechs, academic innovators and diagnostics developers will be presenting new data to prospective funders and partners.

 

Presentations

 

Pitches

Pitch and Partner, Thursday 7 November 2019

Conference Registration

Concrete Commercial Initiatives

Jonathan Van-Tam
08:40

Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

09:20

Sponsored keynote address

TITLE SPONSOR SLOT
10:20

SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK

Funding & Innovation

Karen Gallant
Pitch and Partner
11:15

CARB-X – Accelerating innovation to fight drug-resistant bacteria

Mark Engel
Pitch and Partner
11:35

Utilizing Bacteriophages to Prevent Infections: An Update

Alexander Belcredi
Pitch and Partner
11:55

Developing phage drugs as first-line therapies

Mathew Upton
Pitch and Partner
12:05

Epidermicin NI01, template for a new class of broad spectrum antimicrobials

Robert DeLuccia
Pitch and Partner
12:15

DNA Pol IIIC inhibitors for gram-positive infections, novel first in class antibiotic now in clinic

Greg Merril
Pitch and Partner
12:25

PhageBank - Advancing personalized phage therapy from niche to broad market scale

12:35

Networking Lunch Break

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Christine Årdal
14:10

Roundtable 10 Market Access - overcoming access barriers for smaller markets - considerations for countries and developers

Christian Lillis
14:10

Roundtable 11 Patient Advocacy - what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiativ

Marco Taglietti
14:10

Roundtable 12 Candida auris - a ticking time bomb: responding to an urgent global public health threat

Dave Ousterout
14:10

Roundtable 13 Phage development - Opportunities in development of novel phage therapies

Debbie Goff
14:10

Roundtable 14 Global collaboration – global stakeholder collaboration between clinicians, policy makers, pharmaceutical/diagnostic companies is needed to succeed at ASP

Amy Kirby
14:10

Roundtable 15 Water Quality – understanding transmission of waterborne pathogens and how the international community can combat the spread of resistance through integrating advanced lab techniques

Jeffrey Cies
14:10

Roundtable 16 Drug dosing – anti-infective underdosing and opportunities for customized drug dosing

Kartik Cherabuddi
14:10

Roundtable 2 Controlling c.dif - determining who to test and how to prevent additional outbreaks in the hospital

Richard Vickers
14:10

Roundtable 3 Innovation & stewardship - Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship.

Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes.
Justine Ross
14:10

Roundtable 4 Customizing Epic – the use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center

Colm Leonard
14:10

Roundtable 5 Antimicrobial value assessment - a look into the role of HTA in the UK's testing of novel assessment and delinked payment program

Jay K Varma
14:10

Roundtable 6 Policy in Africa- advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans

Brian Tse
14:10

Roundtable 7 Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Ryan Devies
14:10

Roundtable 8 Advancing Preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs

Jane Knisely
14:10

Roundtable 9 Supporting development - NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening

NIH programs filling the gaps in traditional and non-traditionaltherapeutic discovery & development with grants, contracts,in-vitro and in vivo screening and manufacturing capabilities and more.

Funding & Partnerships

Jean-Pierre Paccaud
Pitch and Partner
15:15

Leveraging sources of public funding to meet gaps in S&M antibiotic financing

How can we avoid the catastrophic disappearance of S&M companies and their unique competencies in antibiotic discovery and development.
Peter Jackson
Pitch and Partner
15:35

UK Centre of Excellence - a global resource for pre-clinical and clinical development, and mobilizing public, private and philanthropic investment

Neil Clark
Pitch and Partner
15:55

XF-73 for the prevention of post-surgical staphylococcal infections

Rusty Bromley
Pitch and Partner
16:05

A novel immunotherapy to fight infection and inflammation

Marc Lemonnier
Pitch and Partner
16:15

Antabio SAS: novel antibacterials targeting critical priority MDR gram-negative pathogens

Marc Gitzinger
Pitch and Partner
16:25

BV100 to treat serious bacterial infections by A.baumannii

16:35

Networking coffee break

Supported by BD

18:15

Drinks Reception

Thomas Cueni
18:15

Welcoming remarks by AMR Industry Alliance

Cocktail Reception hosted by AMR Industry Alliance
last published: 11/Oct/19 22:05

Pitch and Partner, Friday 8 November 2019

08:00

Conference Registration

Tom Lowery
09:25

Keynote Address: The impact of rapid, direct-from-blood diagnostics in enabling changes in clinical decisions and improving outcomes

10:30

Networking coffee break

Investment

Maria Nagy
Pitch and Partner
11:55

Quorum X Diagnostics: A new way of identifying bacteria, without the need for culture or DNA amplification

Matthew Gombrich
Pitch and Partner
12:05

Aperture Bio empiriSTAT UTI: A rapid, direct-out-of-urine method for addressing the rise in antibiotic resistance in urinary tract infections

Piotr Garstecki
Pitch and Partner
12:15

Bacteromic: Intelligence for precision therapies against antimicrobial resistance

Monique Van Hoek
Pitch and Partner
12:25

Discovery of Antimicrobial peptides from Alligator and Komodo Dragons against multi-drug resistant bacteria

12:35

Networking Lunch Break

13:40

Networking Lunch Break Resumes

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Clifford Mcdonald
14:10

Roundtable 10 Microbiome & CDC – Discussing a vision for precision public health novel approaches to treating infection prevention through the microbiome

Minh-Hong Nguyen
14:10

Roundtable 11 Developing diagnostics – novel approaches to development

Minh-Hong Nguyen, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, University of Pittsburgh
Courtney Jones
14:10

Roundtable 12 Infection intervention – using the microbiome to make antibiotics effective again

Mary Millard
14:10

Roundtable 13 Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Wes Kim
14:10

Roundtable 14 SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Jomana Musmar
14:10

Roundtable 15 One Health - The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) recommending federal One Health action to address AMR

Sarah De Clercq
14:10

Roundtable 16 AMR in Belgium – Creating a one health National Action Plan on AMR – rollout and next steps

Sumathi Nambiar
14:10

Roundtable 17 FDA Roundtable discussion

Nick Van Hise
14:10

Roundtable 2 The fecal microbiome - new approaches to the treatment of C. difficile infection

Eugean Jiwanmall
14:10

Roundtable 3 Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensus

Thomas Heymann
14:10

Roundtable 4 AMR and Sepsis - we are all in this together

Eili Klein
14:10

Roundtable 5 Surveillance

Examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR.
Angella Browne
14:10

Roundtable 7 Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Jeanette Mucha
14:10

Roundtable 8 CARB-X Accelerator – Company perspective on CARB-X Accelerator - What worked and what can be improved?

Abigail Colson
14:10

Roundtable 9 Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Wes Kim
14:10

Roundtable: SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Wesley Long
Pitch and Partner
14:10

Rapid antimicrobial resistance prediction from real-time whole genome sequencing

Karin Sauer
Pitch and Partner
14:20

Developing dispersion as an adjunctive therapy to combat biofilm-related infections

last published: 11/Oct/19 22:05

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates